Venous Thromboembolism and Heparin Use in COVID-19 Patients: Juggling between Pragmatic Choices, Suggestions of Medical Societies and the Lack of Guidelines

J Thromb Thrombolysis. 2020 Jul;50(1):68-71. doi: 10.1007/s11239-020-02125-4.

Authors

Angelo Porfidia¹, Roberto Pola^{2

3}

Affiliations

¹ Division of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore, Rome, Italy.
² Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore, Rome, Italy. roberto.pola@unicatt.it.
³ Istituto di Medicina Interna e Geriatria, 9th Floor, C Wing, Room C907 Policlinico A. Gemelli L.go A. Gemelli 8, Rome, 00168, Italy. roberto.pola@unicatt.it.

No abstract available

Publication types

Editorial

MeSH terms

Anticoagulants / adverse effects
Anticoagulants / therapeutic use*
Betacoronavirus / pathogenicity*
Blood Coagulation / drug effects*
COVID-19
COVID-19 Drug Treatment
COVID-19 Testing
Choice Behavior
Clinical Decision-Making
Clinical Laboratory Techniques
Coronavirus Infections / blood
Coronavirus Infections / diagnosis
Coronavirus Infections / drug therapy*
Coronavirus Infections / epidemiology
Coronavirus Infections / virology
Evidence-Based Medicine / standards*
Heparin / adverse effects
Heparin / therapeutic use*
Host-Pathogen Interactions
Humans
Pandemics
Patient Safety
Patient Selection
Pneumonia, Viral / blood
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / epidemiology
Pneumonia, Viral / virology
Practice Guidelines as Topic / standards*
Prevalence
Risk Assessment
Risk Factors
SARS-CoV-2
Treatment Outcome
Venous Thromboembolism / blood
Venous Thromboembolism / epidemiology
Venous Thromboembolism / prevention & control*
Venous Thromboembolism / virology

Substances

Anticoagulants
Heparin